WOONSOCKET, R.I., Nov. 8,
2016 /PRNewswire/ --
Third Quarter Year-over-year Highlights:
- Net revenues increased 15.5% to $44.6
billion
- GAAP operating profit increased 20.9% to $2.8 billion
- GAAP diluted EPS from continuing operations of $1.43
- Adjusted EPS increased 28.0% to $1.64
- GAAP and Adjusted EPS both include a benefit of
approximately 5 cents per share
related to a lower income tax rate primarily due to the resolution
of tax matters previously forecasted for the fourth
quarter
Year-to-date Highlights:
- Cash flow from operations of $7.9
billion
- Generated free cash flow of $6.6
billion
2016 Guidance:
- Full year GAAP diluted EPS lowered and narrowed to
$4.84 to $4.90 from $4.92 to $5.00, including third quarter
acquisition-related integration costs
- Full year Adjusted EPS lowered and narrowed to $5.77 to $5.83 from $5.81
to $5.89
- Provided fourth quarter GAAP diluted EPS of $1.52 to $1.58, excluding acquisition-related
integration costs
- Provided fourth quarter Adjusted EPS of $1.64 to $1.70, up 7.00% to 10.75%
- Raised full year cash flow from operations to $9.3 to $9.5 billion; free cash flow to
$6.8 to $7.0 billion
2017 Preliminary Outlook:
- Provided full year GAAP diluted EPS of $5.16 to $5.33
- Provided full year Adjusted EPS of $5.77 to $5.93
- Both include the projected loss of more than 40 million
retail prescriptions related to new restricted pharmacy
networks
- GAAP diluted EPS includes impact of previously announced
termination of pension plan
CVS Health Corporation (NYSE: CVS) today announced operating
results for the three months ended September 30, 2016.
President and Chief Executive Officer Larry Merlo stated, "We posted a solid third
quarter with the PBM exceeding our expectations and retail
performing at the lower end of our expectations. However, very
recent pharmacy network changes in the marketplace are expected to
cause some retail prescriptions to begin migrating out of our
pharmacies this quarter. In addition, we are currently
experiencing slowing prescription growth in the overall market as
well as a soft seasonal business. These factors combined are
leading us to reduce the mid-point of our guidance for this year by
five cents per share. The network
changes have more significant implications for our 2017 outlook.
While we expect a healthy increase in PBM operating profit growth
in 2017, we expect a decrease in retail operating profit
growth."
Mr. Merlo continued, "We remain confident in our model and we
are targeting 10% growth in Adjusted EPS for the longer term, as we
continue to introduce new and innovative ways to drive value for
patients, payors, and providers."
Revenues
Net revenues for the three months ended September 30, 2016
increased 15.5%, or $6.0 billion, to
$44.6 billion, compared to the three
months ended September 30, 2015. Revenues in the Pharmacy
Services Segment increased 19.2%, or $4.9
billion, to $30.4 billion in
the three months ended September 30, 2016. The increase was
primarily driven by increased pharmacy network claim volume and
growth in specialty pharmacy. Pharmacy network claims processed
during the three months ended September 30, 2016 increased
23.3% to 282.6 million, compared to 229.1 million in the prior
year. The increase in pharmacy network claim volume was primarily
due to the growth in net new business. Mail choice claims processed
during the three months ended September 30, 2016, increased
2.5%, to 22.4 million, compared to 21.9 million in the prior year.
The increase in mail choice claims was primarily driven by the
continued adoption of our Maintenance Choice®
offerings.
Revenues in the Retail/LTC Segment increased 12.5%, or
$2.2 billion, to approximately
$20.1 billion, in the three months
ended September 30, 2016. The increase was primarily driven by
the addition of the long-term care ("LTC") pharmacy operations
acquired as part of the acquisition of Omnicare, Inc. ("Omnicare")
in August 2015, the addition of the
pharmacies and clinics of Target Corporation ("Target") acquired in
December 2015 and pharmacy same store
sales growth. Same store sales increased 2.3% versus the third
quarter of 2015. Pharmacy same store sales rose 3.4% and pharmacy
same store prescription volumes rose 3.0% on a 30-day equivalent
basis. Pharmacy same store sales were negatively affected by
approximately 340 basis points from recent generic drug
introductions. Front store same store sales decreased 1.0%, which
were negatively affected by softer customer traffic partially
offset by an increase in basket size.
For the three months ended September 30, 2016, the generic
dispensing rate increased approximately 160 basis points to 85.4%
in the Pharmacy Services Segment and increased approximately 100
basis points to 85.8% in the Retail/LTC Segment.
Operating Profit
For the three months ended September 30, 2016, consolidated
operating profit increased $486
million, or 20.9%. Excluding acquisition-related integration
costs of $65 million in 2016 and
acquisition-related transaction and integration costs of
$127 million in 2015, consolidated
operating profit increased $424
million, or 17.3%, from $2,458
million for the three months ended September 30, 2015 to $2,882 million for the three months ended
September 30, 2016. For the three months ended September 30, 2016, operating profit increased
$296 million, or 25.3%, to
$1,458 million in the Pharmacy
Services Segment and $130 million, or
7.9%, to $1,773 million in the
Retail/LTC Segment. Excluding acquisition-related integration costs
of $52 million and $12 million in the three months ended
September 30, 2016 and 2015,
respectively, the Retail/LTC Segment operating profit grew
$170 million, or 10.3%, to
$1,825 million for the three months
ended September 30, 2016. Both segments benefited from
increased generic drugs dispensed. The Pharmacy Services Segment
was also positively affected by growth in specialty pharmacy,
growth in Medicare Part D lives and favorable purchasing economics.
The Retail/LTC Segment was also positively affected by the
acquisition of the pharmacies and clinics of Target and the
acquisition of Omnicare's LTC business as well as an improved front
store margin rate. These positive factors for both segments were
partially offset by continued pricing in the Pharmacy Services
Segment and reimbursement pressure in the Retail/LTC Segment.
Net Income and Earnings Per Share
Net income for the three months ended September 30, 2016
was $1.5 billion, an increase of
$294 million or 23.6%. The increase
in net income is primarily due to the $486
million increase in operating profit discussed above
partially offset by a
$101 million loss on early
extinguishment of debt. Net income also benefited, by approximately
$0.05 per share, from a lower income
tax rate, which was primarily due to the resolution of income tax
matters previously forecasted in the fourth quarter.
GAAP earnings per diluted share from continuing operations
("GAAP diluted EPS") for the three months ended September 30,
2016 was $1.43, compared to
$1.10 in the prior year. Adjusted
earnings per share ("Adjusted EPS") for the three months ended
September 30, 2016 and 2015, was $1.64 and $1.28,
respectively. Adjusted EPS excludes $197
million and $160 million of
intangible asset amortization for the three months ended
September 30, 2016 and 2015, respectively. Adjusted EPS for
the three months ended September 30, 2016 also excludes
$65 million of acquisition-related
integration costs and the loss on early extinguishment of debt of
$101 million. Adjusted EPS for the
three months ended September 30, 2015
also excludes $127 million of
acquisition-related transaction and integration costs and
$16 million of acquisition-related
bridge financing costs. Further detail is shown in the Adjusted
Earnings Per Share reconciliation later in this release.
Guidance
The Company lowered and narrowed full year GAAP diluted EPS to
$4.84 to $4.90 from $4.92 to $5.00, including acquisition-related
integration costs recorded in the nine months ended September 30, 2016. The Company lowered and
narrowed full year Adjusted EPS to $5.77 to
$5.83 from $5.81 to $5.89.
Estimated acquisition-related integration costs for the fourth
quarter of 2016 are excluded from the 2016 guidance. Further detail
is shown in the 2016 Adjusted Earnings Per Share Guidance
reconciliation attached to this release.
In the fourth quarter of 2016, the Company expects to deliver
GAAP diluted EPS of $1.52 to $1.58.
The Company expects to deliver Adjusted EPS of $1.64 to $1.70. Further detail is shown in
the 2016 Adjusted Earnings Per Share Guidance reconciliation
attached to this release.
The Company raised cash flow guidance for 2016 and now expects
to deliver cash flow from operations of $9.3
billion to $9.5 billion and 2016 free cash flow of
$6.8 billion to $7.0 billion. Further
detail is shown in the 2016 Free Cash Flow Guidance reconciliation
attached to this release.
2017 Preliminary Outlook
The Company provided a preliminary outlook for 2017. GAAP
diluted EPS is expected to be in the range of $5.16 to $5.33 and Adjusted EPS is expected to be
in the range of $5.77 to
$5.93. Included in this outlook is the impact from the
projected loss of more than 40 million retail prescriptions related
to marketplace changes, including new retail pharmacy networks that
are excluding CVS Pharmacy drugstores. The GAAP outlook includes
the expected impact of the previously-announced termination of one
of the Company's pension plans and excludes the impact of
integration costs related to the acquisition of Omnicare, which
will be updated as the year progresses. Further detail is shown in
the 2017 Preliminary Outlook reconciliation later in this
release.
New Share Repurchase Authorization
The share repurchase authorization approved in December 2014 is nearing completion with
approximately $3.7 billion remaining.
Reflecting the board's ongoing commitment to returning value to
shareholders, the Company announced that, consistent with its
practice, the board of directors approved a new share repurchase
program for up to $15 billion of the
Company's outstanding common stock. Combined with the approximately
$3.7 billion that remains from the
2014 program, the Company has approximately $18.7 billion available for share repurchases.
The share repurchase authorization, which is effective immediately
and is expected to be completed over a multi-year period, permits
the Company to effect the repurchases from time to time through a
combination of open market repurchases, privately negotiated
transactions, accelerated share repurchase transactions, and/or
other derivative transactions.
Real Estate Program
During the three months ended September 30, 2016, the
Company opened 48 new retail stores and closed 6 retail stores. In
addition, the Company relocated 11 retail stores. As of
September 30, 2016, the Company operated 9,694 retail stores,
including pharmacies in Target stores, in 49 states, the
District of Columbia, Puerto Rico and Brazil.
Teleconference and Webcast
The Company will be holding a conference call today for the
investment community at 8:30 am (ET)
to discuss its quarterly results. An audio webcast of the call will
be broadcast simultaneously for all interested parties through the
Investor Relations section of the CVS Health website at
http://investors.cvshealth.com. This webcast will be archived and
available on the website for a one-year period following the
conference call.
About the Company
CVS Health is a pharmacy innovation company helping people on
their path to better health. Through its more than 9,600 retail
pharmacies, more than 1,100 walk-in medical clinics, a leading
pharmacy benefits manager with more than 80 million plan members, a
dedicated senior pharmacy care business serving more than one
million patients per year, and expanding specialty pharmacy
services, the Company enables people, businesses and communities to
manage health in more affordable and effective ways. This unique
integrated model increases access to quality care, delivers better
health outcomes and lowers overall health care costs. Find more
information about how CVS Health is shaping the future of health at
https://www.cvshealth.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the federal securities laws. By their nature, all
forward-looking statements involve risks and uncertainties. Actual
results may differ materially from those contemplated by the
forward-looking statements for a number of reasons as described in
our Securities and Exchange Commission filings, including those set
forth in the Risk Factors section and under the section entitled
"Cautionary Statement Concerning Forward-Looking Statements" in our
most recently filed Annual Report on Form 10-K and Quarterly
Report on Form 10-Q.
— Tables Follow —
CVS HEALTH
CORPORATION Condensed Consolidated Statements of
Income (Unaudited)
|
|
|
Three Months Ended
September
30,
|
|
Nine
Months Ended
September 30,
|
In millions, except per share amounts
|
2016
|
|
2015
|
|
2016
|
|
2015
|
|
|
|
|
|
|
|
|
Net
revenues
|
$
|
44,615
|
|
|
$
|
38,644
|
|
|
$
|
131,555
|
|
|
$
|
112,144
|
|
Cost of
revenues
|
37,123
|
|
|
31,983
|
|
|
110,304
|
|
|
92,917
|
|
Gross
profit
|
7,492
|
|
|
6,661
|
|
|
21,251
|
|
|
19,227
|
|
Operating
expenses
|
4,675
|
|
|
4,330
|
|
|
13,908
|
|
|
12,502
|
|
Operating
profit
|
2,817
|
|
|
2,331
|
|
|
7,343
|
|
|
6,725
|
|
Interest expense,
net
|
253
|
|
|
261
|
|
|
816
|
|
|
562
|
|
Loss on early
extinguishment of debt
|
101
|
|
|
—
|
|
|
643
|
|
|
—
|
|
Income before income
tax provision
|
2,463
|
|
|
2,070
|
|
|
5,884
|
|
|
6,163
|
|
Income tax
provision
|
921
|
|
|
833
|
|
|
2,271
|
|
|
2,433
|
|
Income from
continuing operations
|
1,542
|
|
|
1,237
|
|
|
3,613
|
|
|
3,730
|
|
Income (loss) from
discontinued operations, net of tax
|
(1)
|
|
|
10
|
|
|
(1)
|
|
|
10
|
|
Net income
|
1,541
|
|
|
1,247
|
|
|
3,612
|
|
|
3,740
|
|
Net income
attributable to noncontrolling interest
|
(1)
|
|
|
(1)
|
|
|
(2)
|
|
|
(1)
|
|
Net income
attributable to CVS Health
|
$
|
1,540
|
|
|
$
|
1,246
|
|
|
$
|
3,610
|
|
|
$
|
3,739
|
|
|
|
|
|
|
|
|
|
Basic earnings per
share:
|
|
|
|
|
|
|
|
Income from
continuing operations attributable to CVS Health
|
$
|
1.44
|
|
|
$
|
1.10
|
|
|
$
|
3.34
|
|
|
$
|
3.31
|
|
Income from
discontinued operations attributable to CVS Health
|
$
|
—
|
|
|
$
|
0.01
|
|
|
$
|
—
|
|
|
$
|
0.01
|
|
Net income
attributable to CVS Health
|
$
|
1.44
|
|
|
$
|
1.11
|
|
|
$
|
3.34
|
|
|
$
|
3.32
|
|
Weighted average
basic shares outstanding
|
1,068
|
|
|
1,114
|
|
|
1,076
|
|
|
1,122
|
|
|
|
|
|
|
|
|
|
Diluted earnings per
share:
|
|
|
|
|
|
|
|
Income from
continuing operations attributable to CVS Health
|
$
|
1.43
|
|
|
$
|
1.10
|
|
|
$
|
3.32
|
|
|
$
|
3.28
|
|
Income from
discontinued operations attributable to CVS Health
|
$
|
—
|
|
|
$
|
0.01
|
|
|
$
|
—
|
|
|
$
|
0.01
|
|
Net income
attributable to CVS Health
|
$
|
1.43
|
|
|
$
|
1.11
|
|
|
$
|
3.32
|
|
|
$
|
3.29
|
|
Weighted average
diluted shares outstanding
|
1,073
|
|
|
1,121
|
|
|
1,082
|
|
|
1,130
|
|
Dividends declared
per share
|
$
|
0.425
|
|
|
$
|
0.350
|
|
|
$
|
1.275
|
|
|
$
|
1.050
|
|
CVS HEALTH
CORPORATION Condensed Consolidated Balance
Sheets (Unaudited)
|
|
|
|
September
30,
|
|
December
31,
|
In millions, except per share amounts
|
|
2016
|
|
2015
|
Assets:
|
|
|
|
|
Cash and cash
equivalents
|
|
$
|
2,189
|
|
|
$
|
2,459
|
|
Short-term
investments
|
|
74
|
|
|
88
|
|
Accounts receivable,
net
|
|
13,625
|
|
|
11,888
|
|
Inventories
|
|
14,348
|
|
|
14,001
|
|
Other current
assets
|
|
703
|
|
|
722
|
|
Total current
assets
|
|
30,939
|
|
|
29,158
|
|
Property and
equipment, net
|
|
9,901
|
|
|
9,855
|
|
Goodwill
|
|
38,214
|
|
|
38,106
|
|
Intangible assets,
net
|
|
13,567
|
|
|
13,878
|
|
Other
assets
|
|
1,535
|
|
|
1,440
|
|
Total
assets
|
|
$
|
94,156
|
|
|
$
|
92,437
|
|
|
|
|
|
|
Liabilities:
|
|
|
|
|
Accounts
payable
|
|
$
|
7,584
|
|
|
$
|
7,490
|
|
Claims and discounts
payable
|
|
9,178
|
|
|
7,653
|
|
Accrued
expenses
|
|
8,856
|
|
|
6,829
|
|
Short-term
debt
|
|
340
|
|
|
—
|
|
Current portion of
long-term debt
|
|
783
|
|
|
1,197
|
|
Total current
liabilities
|
|
26,741
|
|
|
23,169
|
|
Long-term
debt
|
|
25,610
|
|
|
26,267
|
|
Deferred income
taxes
|
|
4,254
|
|
|
4,217
|
|
Other long-term
liabilities
|
|
1,597
|
|
|
1,542
|
|
Commitments and
contingencies
|
|
—
|
|
|
—
|
|
Redeemable
noncontrolling interest
|
|
—
|
|
|
39
|
|
|
|
|
|
|
Shareholders'
equity:
|
|
|
|
|
CVS Health
shareholders' equity:
|
|
|
|
|
Preferred stock, par
value $0.01: 0.1 shares authorized; none issued or
outstanding
|
|
—
|
|
|
—
|
|
Common stock, par
value $0.01: 3,200 shares authorized; 1,705 shares issued and
1,066
|
|
|
|
|
shares outstanding at
September 30, 2016 and 1,699 shares issued and 1,101
shares
|
|
|
|
|
outstanding at
December 31, 2015
|
|
17
|
|
|
17
|
|
Treasury stock, at
cost: 638 shares at September 30, 2016 and 597 shares at
December 31,
|
|
|
|
|
2015
|
|
(32,991)
|
|
|
(28,886)
|
|
Shares held in trust:
1 share at September 30, 2016 and December 31,
2015
|
|
(31)
|
|
|
(31)
|
|
Capital
surplus
|
|
31,541
|
|
|
30,948
|
|
Retained
earnings
|
|
37,732
|
|
|
35,506
|
|
Accumulated other
comprehensive income (loss)
|
|
(319)
|
|
|
(358)
|
|
Total CVS Health
shareholders' equity
|
|
35,949
|
|
|
37,196
|
|
Noncontrolling
interest
|
|
5
|
|
|
7
|
|
Total shareholders'
equity
|
|
35,954
|
|
|
37,203
|
|
Total liabilities and
shareholders' equity
|
|
$
|
94,156
|
|
|
$
|
92,437
|
|
CVS HEALTH
CORPORATION Condensed Consolidated Statements of Cash
Flows (Unaudited)
|
|
|
|
Nine
Months Ended
September
30,
|
In millions
|
|
2016
|
|
2015
|
Cash flows from
operating activities:
|
|
|
|
|
Cash receipts from
customers
|
|
$
|
128,545
|
|
|
$
|
108,324
|
|
Cash paid for
inventory and prescriptions dispensed by retail network
pharmacies
|
|
(106,371)
|
|
|
(89,530)
|
|
Cash paid to other
suppliers and employees
|
|
(11,092)
|
|
|
(11,240)
|
|
Interest
received
|
|
14
|
|
|
15
|
|
Interest
paid
|
|
(954)
|
|
|
(423)
|
|
Income taxes
paid
|
|
(2,194)
|
|
|
(2,305)
|
|
Net cash provided by
operating activities
|
|
7,948
|
|
|
4,841
|
|
|
|
|
|
|
Cash flows from
investing activities:
|
|
|
|
|
Purchases of property
and equipment
|
|
(1,607)
|
|
|
(1,490)
|
|
Proceeds from
sale-leaseback transactions
|
|
230
|
|
|
34
|
|
Proceeds from sale of
property and equipment and other assets
|
|
22
|
|
|
28
|
|
Acquisitions (net of
cash acquired) and other investments
|
|
(333)
|
|
|
(9,503)
|
|
Purchase of
available-for-sale investments
|
|
(40)
|
|
|
(184)
|
|
Sale or maturity of
available-for-sale investments
|
|
76
|
|
|
115
|
|
Net cash used in
investing activities
|
|
(1,652)
|
|
|
(11,000)
|
|
|
|
|
|
|
Cash flows from
financing activities:
|
|
|
|
|
Increase in
short-term debt
|
|
340
|
|
|
(685)
|
|
Proceeds from
issuance of long-term debt
|
|
3,455
|
|
|
14,808
|
|
Repayments of
long-term debt
|
|
(5,185)
|
|
|
(2,898)
|
|
Purchase of
noncontrolling interest in subsidiary
|
|
(39)
|
|
|
—
|
|
Payments of
contingent consideration
|
|
(26)
|
|
|
—
|
|
Dividends
paid
|
|
(1,384)
|
|
|
(1,185)
|
|
Proceeds from
exercise of stock options
|
|
205
|
|
|
277
|
|
Excess tax benefits
from stock-based compensation
|
|
72
|
|
|
132
|
|
Repurchase of common
stock
|
|
(4,000)
|
|
|
(3,871)
|
|
Other
|
|
(6)
|
|
|
(2)
|
|
Net cash provided by
(used in) financing activities
|
|
(6,568)
|
|
|
6,576
|
|
Effect of exchange
rates on cash and cash equivalents
|
|
2
|
|
|
(8)
|
|
Net increase
(decrease) in cash and cash equivalents
|
|
(270)
|
|
|
409
|
|
Cash and cash
equivalents at the beginning of the period
|
|
2,459
|
|
|
2,481
|
|
Cash and cash
equivalents at the end of the period
|
|
$
|
2,189
|
|
|
$
|
2,890
|
|
|
|
|
|
|
Reconciliation of net
income to net cash provided by operating activities:
|
|
|
|
|
Net income
|
|
$
|
3,612
|
|
|
$
|
3,740
|
|
Adjustments required
to reconcile net income to net cash provided by operating
activities:
|
|
|
|
|
Depreciation and
amortization
|
|
1,847
|
|
|
1,510
|
|
Stock-based
compensation
|
|
166
|
|
|
175
|
|
Loss on early
extinguishment of debt
|
|
643
|
|
|
—
|
|
Deferred income taxes
and other non-cash items
|
|
119
|
|
|
(184)
|
|
Change in operating
assets and liabilities, net of effects of acquisitions:
|
|
|
|
|
Accounts receivable,
net
|
|
(1,714)
|
|
|
(2,530)
|
|
Inventories
|
|
(337)
|
|
|
(893)
|
|
Other current
assets
|
|
2
|
|
|
591
|
|
Other
assets
|
|
(86)
|
|
|
(13)
|
|
Accounts payable and
claims and discounts payable
|
|
1,570
|
|
|
2,038
|
|
Accrued
expenses
|
|
2,077
|
|
|
523
|
|
Other long-term
liabilities
|
|
49
|
|
|
(116)
|
|
Net cash provided by
operating activities
|
|
$
|
7,948
|
|
|
$
|
4,841
|
|
Non-GAAP Financial
Measures
|
|
The following
provides reconciliations of certain non-GAAP financial measures
presented in this press release to the most directly comparable
financial measures calculated and presented in accordance with
GAAP. The Company uses the non-GAAP measures "Adjusted EPS" and
"Free Cash Flow" to assess and analyze underlying business
performance and trends. Management believes that providing these
non-GAAP measures enhances investors' understanding of the
Company's performance.
|
|
The Company defines
Adjusted Earnings per Share, or Adjusted EPS, as net income
excluding the impact of the amortization of intangible assets,
acquisition-related transaction and integration costs,
acquisition-related bridge financing costs, charge related to a
disputed 1999 legal settlement and loss on early extinguishment of
debt divided by the Company's weighted average diluted shares
outstanding. The Company believes that this measure enhances
investors' ability to compare the Company's past financial
performance with its current performance.
|
|
The Company defines
Free Cash Flow as net cash provided by operating activities less
net additions to properties and equipment (i.e., additions to
property and equipment plus proceeds from sale-leaseback
transactions). Management uses this non-GAAP financial measure for
internal comparisons and finds it useful in assessing
year-over-year cash flow performance.
|
|
These non-GAAP
financial measures are provided as supplemental information to the
financial measures presented in this press release that are
calculated and presented in accordance with GAAP. Adjusted EPS
should be considered in addition to, rather than as a substitute
for, income before income tax provision as a measure of our
performance. Free Cash Flow should be considered in addition to,
rather than as a substitute for, net cash provided by operating
activities as a measure of our liquidity. The Company's definitions
of Adjusted EPS and Free Cash Flow may not be comparable to
similarly titled measurements reported by other
companies.
|
|
The Company has not
provided a reconciliation of the long-term Adjusted EPS target
announced today to GAAP EPS. The Company is unable to
reasonably estimate the GAAP items excluded from the multi-year,
long-term Adjusted EPS target.
|
|
Adjusted Earnings
Per Share (Unaudited)
|
|
The following is a
reconciliation of income before income tax provision to Adjusted
EPS:
|
|
|
|
Three Months Ended
September
30,
|
|
Nine
Months Ended
September 30,
|
In millions, except per share amounts
|
|
2016
|
|
2015
|
|
2016
|
|
2015
|
Income before income
tax provision
|
|
$
|
2,463
|
|
|
$
|
2,070
|
|
|
$
|
5,884
|
|
|
$
|
6,163
|
|
Non-GAAP
adjustments:
|
|
|
|
|
|
|
|
|
Amortization of
intangible assets
|
|
197
|
|
|
160
|
|
|
593
|
|
|
419
|
|
Acquisition-related
transaction and integration costs(1)
|
|
65
|
|
|
127
|
|
|
207
|
|
|
147
|
|
Acquisition-related
bridge financing costs(1)
|
|
—
|
|
|
16
|
|
|
—
|
|
|
52
|
|
Charge related to a
disputed 1999 legal settlement
|
|
—
|
|
|
—
|
|
|
3
|
|
|
—
|
|
Loss on early
extinguishment of debt
|
|
101
|
|
|
—
|
|
|
643
|
|
|
—
|
|
Adjusted income
before income tax provision
|
|
2,826
|
|
|
2,373
|
|
|
7,330
|
|
|
6,781
|
|
Adjusted income tax
provision
|
|
1,063
|
|
|
933
|
|
|
2,832
|
|
|
2,658
|
|
Adjusted income from
continuing operations
|
|
1,763
|
|
|
1,440
|
|
|
4,498
|
|
|
4,123
|
|
Net income
attributable to noncontrolling interest
|
|
(1)
|
|
|
(1)
|
|
|
(2)
|
|
|
(1)
|
|
Adjusted income
allocable to participating securities
|
|
(8)
|
|
|
(6)
|
|
|
(23)
|
|
|
(18)
|
|
Adjusted income from
continuing operations attributable to
CVS Health
|
|
$
|
1,754
|
|
|
$
|
1,433
|
|
|
$
|
4,473
|
|
|
$
|
4,104
|
|
|
|
|
|
|
|
|
|
|
Weighted average
diluted shares outstanding
|
|
1,073
|
|
|
1,121
|
|
|
1,082
|
|
|
1,130
|
|
Adjusted
EPS
|
|
$
|
1.64
|
|
|
$
|
1.28
|
|
|
$
|
4.13
|
|
|
$
|
3.63
|
|
|
(1) Costs
associated with the acquisitions of Omnicare and the pharmacies and
clinics of Target.
|
Free Cash
Flow (Unaudited)
|
|
The following is a
reconciliation of net cash provided by operating activities to free
cash flow:
|
|
|
|
Nine
Months Ended
September
30,
|
In millions
|
|
2016
|
|
2015
|
|
|
|
|
|
Net cash provided by
operating activities
|
|
$
|
7,948
|
|
|
$
|
4,841
|
|
Subtract: Additions
to property and equipment
|
|
(1,607)
|
|
|
(1,490)
|
|
Add: Proceeds from
sale-leaseback transactions
|
|
230
|
|
|
34
|
|
Free cash
flow
|
|
$
|
6,571
|
|
|
$
|
3,385
|
|
Supplemental
Information (Unaudited)
|
|
The Company evaluates
its Pharmacy Services Segment and Retail/LTC Segment performance
based on net revenue, gross profit and operating profit before the
effect of nonrecurring charges and gains and certain intersegment
activities. The Company evaluates the performance of its Corporate
Segment based on operating expenses before the effect of
nonrecurring charges and gains and certain intersegment activities.
The following is a reconciliation of the Company's segments to the
accompanying condensed consolidated financial
statements:
|
|
In millions
|
|
Pharmacy
Services
Segment(1)
|
|
Retail/LTC
Segment
|
|
Corporate
Segment
|
|
Intersegment
Eliminations(2)
|
|
Consolidated
Totals
|
Three Months
Ended
|
|
|
|
|
|
|
|
|
|
|
September 30,
2016:
|
|
|
|
|
|
|
|
|
|
|
Net
revenues
|
|
$
|
30,429
|
|
|
$
|
20,143
|
|
|
$
|
—
|
|
|
$
|
(5,957)
|
|
|
$
|
44,615
|
|
Gross
profit(3)
|
|
1,797
|
|
|
5,893
|
|
|
—
|
|
|
(198)
|
|
|
7,492
|
|
Operating profit
(loss)(4)(5)
|
|
1,458
|
|
|
1,773
|
|
|
(229)
|
|
|
(185)
|
|
|
2,817
|
|
September 30,
2015:
|
|
|
|
|
|
|
|
|
|
|
Net
revenues
|
|
25,528
|
|
|
17,912
|
|
|
—
|
|
|
(4,796)
|
|
|
38,644
|
|
Gross
profit
|
|
1,468
|
|
|
5,373
|
|
|
—
|
|
|
(180)
|
|
|
6,661
|
|
Operating profit
(loss)(4)(5)
|
|
1,162
|
|
|
1,643
|
|
|
(309)
|
|
|
(165)
|
|
|
2,331
|
|
Nine Months
Ended
|
|
|
|
|
|
|
|
|
|
|
September 30,
2016:
|
|
|
|
|
|
|
|
|
|
|
Net
revenues
|
|
88,704
|
|
|
60,253
|
|
|
—
|
|
|
(17,402)
|
|
|
131,555
|
|
Gross
profit(3)
|
|
4,266
|
|
|
17,560
|
|
|
—
|
|
|
(575)
|
|
|
21,251
|
|
Operating profit
(loss)(4)(5)
|
|
3,278
|
|
|
5,255
|
|
|
(661)
|
|
|
(529)
|
|
|
7,343
|
|
September 30,
2015:
|
|
|
|
|
|
|
|
|
|
|
Net
revenues
|
|
73,849
|
|
|
52,105
|
|
|
—
|
|
|
(13,810)
|
|
|
112,144
|
|
Gross
profit
|
|
3,735
|
|
|
15,990
|
|
|
—
|
|
|
(498)
|
|
|
19,227
|
|
Operating profit
(loss)(4)(5)
|
|
2,837
|
|
|
5,050
|
|
|
(712)
|
|
|
(450)
|
|
|
6,725
|
|
|
(1) Net
revenues of the Pharmacy Services Segment include approximately
$2.5 billion and $2.1 billion of retail co-payments for the three
months ended September 30, 2016 and 2015, respectively, as
well as $8.1 billion and $6.8 billion of retail co-payments for the
nine months ended September 30, 2016 and 2015,
respectively.
|
(2)
Intersegment eliminations relate to intersegment revenue
generating activities that occur between the Pharmacy Services
Segment and the Retail/LTC Segment. These occur in the following
ways: when members of Pharmacy Services Segment clients ("members")
fill prescriptions at our retail stores to purchase covered
products, when members enrolled in programs such as Maintenance
Choice ® elect to pick up maintenance prescriptions at
one of our retail stores instead of receiving them through the
mail, or when members have prescriptions filled at our long-term
care pharmacies. When these occur, both the Pharmacy Services and
Retail/LTC segments record the revenues, gross profit and operating
profit on a standalone basis.
|
(3) The
Retail/LTC Segment gross profit for the three and nine months ended
September 30, 2016 includes $5 million and $15 million,
respectively, of acquisition-related integration costs. The
integration costs are related to the acquisitions of Omnicare and
the pharmacies and clinics of Target.
|
(4) The
Retail/LTC Segment operating profit for the three and nine months
ended September 30, 2016 includes $52 million and $194 million,
respectively, of acquisition-related integration costs. The
Retail/LTC Segment operating profit for the three and nine months
ended September 30, 2015 includes $12 million of
acquisition-related integration costs. The integration costs are
related to the acquisitions of Omnicare and the pharmacies and
clinics of Target.
|
(5) The
Corporate Segment operating loss for the three and nine months
ended September 30, 2016 includes $13 million of integration costs.
The Corporate Segment operating loss for the three and nine months
ended September 30, 2015 includes $115 million and $135 million,
respectively, of acquisition-related transaction and integration
costs.
|
Supplemental
Information (Unaudited)
|
|
Pharmacy Services
Segment
|
|
The following table
summarizes the Pharmacy Services Segment's performance for the
respective periods:
|
|
|
|
Three Months
Ended
September 30,
|
|
Nine Months
Ended
September 30,
|
In millions
|
|
2016
|
|
2015
|
|
2016
|
|
2015
|
|
|
|
|
|
|
|
|
|
Net
revenues
|
|
$
|
30,429
|
|
|
$
|
25,528
|
|
|
$
|
88,704
|
|
|
$
|
73,849
|
|
Gross
profit
|
|
1,797
|
|
|
1,468
|
|
|
4,266
|
|
|
3,735
|
|
Gross profit % of net
revenues
|
|
5.9%
|
|
|
5.8%
|
|
|
4.8%
|
|
|
5.1%
|
|
Operating
expenses
|
|
339
|
|
|
306
|
|
|
988
|
|
|
898
|
|
Operating expense %
of net revenues
|
|
1.1%
|
|
|
1.2%
|
|
|
1.1%
|
|
|
1.2%
|
|
Operating
profit
|
|
1,458
|
|
|
1,162
|
|
|
3,278
|
|
|
2,837
|
|
Operating profit % of
net revenues
|
|
4.8%
|
|
|
4.6%
|
|
|
3.7%
|
|
|
3.8%
|
|
Net
revenues:
|
|
|
|
|
|
|
|
|
Mail
choice(1)
|
|
$
|
10,872
|
|
|
$
|
9,735
|
|
|
$
|
31,668
|
|
|
$
|
27,592
|
|
Pharmacy
network(2)
|
|
19,469
|
|
|
15,716
|
|
|
56,783
|
|
|
46,043
|
|
Other
|
|
88
|
|
|
77
|
|
|
253
|
|
|
214
|
|
Pharmacy claims
processed:
|
|
|
|
|
|
|
|
|
Total
|
|
305.0
|
|
|
251.0
|
|
|
912.5
|
|
|
752.3
|
|
Mail
choice(1)
|
|
22.4
|
|
|
21.9
|
|
|
66.3
|
|
|
63.5
|
|
Pharmacy
network(2)
|
|
282.6
|
|
|
229.1
|
|
|
846.2
|
|
|
688.8
|
|
Generic dispensing
rate:
|
|
|
|
|
|
|
|
|
Total
|
|
85.4%
|
|
|
83.8%
|
|
|
85.4%
|
|
|
83.7%
|
|
Mail
choice(1)
|
|
78.5%
|
|
|
76.5%
|
|
|
78.0%
|
|
|
76.3%
|
|
Pharmacy
network(2)
|
|
86.0%
|
|
|
84.5%
|
|
|
85.9%
|
|
|
84.4%
|
|
Mail choice
penetration rate
|
|
18.1%
|
|
|
21.1%
|
|
|
18.0%
|
|
|
20.5%
|
|
|
(1) Mail
choice is defined as claims filled at a Pharmacy Services mail
facility, which include specialty mail claims inclusive of
Specialty Connect® claims filled at our retail stores,
as well as prescriptions filled at our retail stores under the
Maintenance Choice® program.
|
(2)
Pharmacy network net revenues, claims processed and generic
dispensing rates do not include Maintenance Choice, which are
included within the mail choice category. Pharmacy network is
defined as claims filled at retail stores and specialty retail
pharmacies, including our retail stores and long-term care
pharmacies, but excluding Maintenance Choice activity.
|
Supplemental
Information (Unaudited)
|
|
Retail/LTC
Segment
|
|
The following table
summarizes the Retail/LTC Segment's performance for the respective
periods:
|
|
|
|
Three Months
Ended
September 30,
|
|
Nine Months
Ended
September 30,
|
In millions
|
|
2016
|
|
2015
|
|
2016
|
|
2015
|
|
|
|
|
|
|
|
|
|
Net
revenues
|
|
$
|
20,143
|
|
|
$
|
17,912
|
|
|
$
|
60,253
|
|
|
$
|
52,105
|
|
Gross
profit(1)
|
|
5,893
|
|
|
5,373
|
|
|
17,560
|
|
|
15,990
|
|
Gross profit % of net
revenues
|
|
29.3%
|
|
|
30.0%
|
|
|
9.1%
|
|
|
30.7%
|
|
Operating
expenses(2)
|
|
4,120
|
|
|
3,730
|
|
|
12,305
|
|
|
10,940
|
|
Operating expense %
of net revenues
|
|
20.5%
|
|
|
20.8%
|
|
|
20.4%
|
|
|
21.0%
|
|
Operating
profit
|
|
1,773
|
|
|
1,643
|
|
|
5,255
|
|
|
5,050
|
|
Operating profit % of
net revenues
|
|
8.8%
|
|
|
9.2%
|
|
|
8.7%
|
|
|
9.7%
|
|
Prescriptions filled
(90 Day = 3 Rx)(3)
|
|
302.9
|
|
|
258.7
|
|
|
908.9
|
|
|
744.1
|
|
Net revenue increase
(decrease):
|
|
|
|
|
|
|
|
|
Total
|
|
12.5%
|
|
|
6.9%
|
|
|
15.6%
|
|
|
4.0%
|
|
Pharmacy
|
|
15.3%
|
|
|
10.4%
|
|
|
19.9%
|
|
|
7.0%
|
|
Front
store
|
|
0.8%
|
|
|
(2.4)%
|
|
|
0.9%
|
|
|
(3.7)%
|
|
Total prescription
volume (90 Day = 3 Rx)(3)
|
|
17.1%
|
|
|
10.7%
|
|
|
22.1%
|
|
|
7.7%
|
|
Same store increase
(decrease)(4):
|
|
|
|
|
|
|
|
|
Total
sales
|
|
2.3%
|
|
|
1.7%
|
|
|
2.8%
|
|
|
1.1%
|
|
Pharmacy
sales
|
|
3.4%
|
|
|
4.6%
|
|
|
4.3%
|
|
|
4.3%
|
|
Front store
sales
|
|
(1.0)%
|
|
|
(5.8)%
|
|
|
(1.0)%
|
|
|
(6.6)%
|
|
Prescription volume
(90 Day = 3 Rx)(3)
|
|
3.0%
|
|
|
4.4%
|
|
|
4.1%
|
|
|
4.8%
|
|
Generic dispensing
rate
|
|
85.8%
|
|
|
84.8%
|
|
|
85.8%
|
|
|
84.7%
|
|
Pharmacy % of total
revenues
|
|
76.0%
|
|
|
74.1%
|
|
|
75.2%
|
|
|
72.5%
|
|
|
(1) Gross
profit for the three and nine months ended September 30, 2016
includes $5 million and $15 million, respectively, of
acquisition-related integration costs related to the acquisitions
of Omnicare and the pharmacies and clinics of Target.
|
(2)
Operating expenses for the three and nine months ended
September 30, 2016 includes $47 million and $179 million,
respectively, of acquisition-related integration costs related to
the acquisitions of Omnicare and the pharmacies and clinics of
Target. Operating expenses for the three and nine months ended
September 30, 2015 includes $12 million of acquisition-related
integration costs related to the acquisitions of Omnicare and the
pharmacies and clinics of Target.
|
(3)
Includes the adjustment to convert 90-day, non-specialty
prescriptions to the equivalent of three 30-day prescriptions. This
adjustment reflects the fact that these prescriptions include
approximately three times the amount of product days supplied
compared to a normal prescription.
|
(4) Same
store sales and prescriptions exclude revenues from MinuteClinic,
and revenue and prescriptions from stores in Brazil, long-term care
operations and from commercialization services.
|
2016 Adjusted
Earnings Per Share Guidance (Unaudited)
|
|
The following
reconciliation of estimated income before income tax provision to
estimated adjusted earnings per share contains forward-looking
information. All forward-looking information involves risks and
uncertainties. Actual results may differ materially from those
contemplated by the forward-looking information for a number of
reasons as described in our Securities and Exchange Commission
filings, including those set forth in the Risk Factors section and
under the section entitled "Cautionary Statement Concerning
Forward-Looking Statements" in our most recently filed Annual
Report on Form 10-K and Quarterly Report on Form 10-Q. See also
"Non-GAAP Financial Measures" above for more information on how we
calculate Adjusted EPS.
|
|
In millions, except per share amounts
|
|
Year
Ending
December 31, 2016
|
|
|
|
|
|
Income before income
tax provision(1)
|
|
$
|
8,588
|
|
|
$
|
8,689
|
|
Non-GAAP
adjustments:
|
|
|
|
|
Amortization of
intangible assets
|
|
798
|
|
|
798
|
|
Acquisition-related
integration costs(1)
|
|
207
|
|
|
207
|
|
Loss on early
extinguishment of debt
|
|
643
|
|
|
643
|
|
Charge related to a
disputed 1999 legal settlement
|
|
3
|
|
|
3
|
|
Adjusted income
before income tax provision
|
|
10,239
|
|
|
10,340
|
|
Adjusted income tax
provision
|
|
3,973
|
|
|
4,012
|
|
Adjusted income from
continuing operations
|
|
6,266
|
|
|
6,328
|
|
Net income
attributable to noncontrolling interest
|
|
(2)
|
|
|
(2)
|
|
Income allocable to
participating securities
|
|
(32)
|
|
|
(32)
|
|
Adjusted income from
continuing operations attributable to CVS Health
|
|
$
|
6,232
|
|
|
$
|
6,294
|
|
|
|
|
|
|
Weighted average
diluted shares outstanding
|
|
1,080
|
|
|
1,080
|
|
Adjusted earnings per
share
|
|
$
|
5.77
|
|
|
$
|
5.83
|
|
|
|
|
|
|
|
In millions, except per share amounts
|
|
Three Months
Ending
December
31, 2016
|
|
|
|
|
|
Income before income
tax provision(2)
|
|
$
|
2,704
|
|
|
$
|
2,805
|
|
Non-GAAP
adjustments:
|
|
|
|
|
Amortization of
intangible assets
|
|
205
|
|
|
205
|
|
Adjusted income
before income tax provision
|
|
2,909
|
|
|
3,010
|
|
Adjusted income tax
provision
|
|
1,140
|
|
|
1,180
|
|
Adjusted income from
continuing operations
|
|
1,769
|
|
|
1,830
|
|
Net income
attributable to noncontrolling interest
|
|
—
|
|
|
—
|
|
Income allocable to
participating securities
|
|
(9)
|
|
|
(9)
|
|
Adjusted income from
continuing operations attributable to CVS Health
|
|
$
|
1,760
|
|
|
$
|
1,821
|
|
|
|
|
|
|
Weighted average
diluted shares outstanding
|
|
1,073
|
|
|
1,073
|
|
Adjusted earnings per
share
|
|
$
|
1.64
|
|
|
$
|
1.70
|
|
|
(1) 2016
guidance includes integration costs for the acquisitions of
Omnicare and the pharmacies and clinics of Target for the nine
months ended September 30, 2016 and excludes estimated integration
costs for the period from October 1, 2016 to December 31,
2016.
|
(2) Estimated
integration costs related to the acquisitions of Omnicare and the
pharmacies and clinics of Target for the period from October 1,
2016 to December 31, 2016 are excluded from 2016
guidance.
|
2016 Free Cash
Flow Guidance (Unaudited)
|
|
The following
reconciliation of net cash provided by operating activities to free
cash flow contains forward-looking information. All forward-looking
information involves risks and uncertainties. Actual results may
differ materially from those contemplated by the forward-looking
information for a number of reasons as described in our Securities
and Exchange Commission filings, including those set forth in the
Risk Factors section and under the section entitled "Cautionary
Statement Concerning Forward-Looking Statements" in our most
recently filed Annual Report on Form 10-K and Quarterly Report on
Form 10-Q. See also "Non-GAAP Financial Measures" above for more
information on how we calculate Free Cash Flow.
|
|
In millions
|
|
Year
Ending
December 31, 2016
|
|
|
|
|
|
Net cash provided by
operating activities
|
|
$
|
9,075
|
|
|
$
|
9,270
|
|
Subtract: Additions
to property and equipment
|
|
(2,550)
|
|
|
(2,500)
|
|
Add: Proceeds from
sale-leaseback transactions
|
|
275
|
|
|
230
|
|
Free cash
flow
|
|
$
|
6,800
|
|
|
$
|
7,000
|
|
2017 Preliminary
Outlook Adjusted Earnings Per
Share (Unaudited)
|
|
The following
reconciliation of estimated income before income tax provision to
estimated adjusted earnings per share contains forward-looking
information. All forward-looking information involves risks and
uncertainties. Actual results may differ materially from those
contemplated by the forward-looking information for a number of
reasons as described in our Securities and Exchange Commission
filings, including those set forth in the Risk Factors section and
under the section entitled "Cautionary Statement Concerning
Forward-Looking Statements" in our most recently filed Annual
Report on Form 10-K and Quarterly Report on Form 10-Q. See also
"Non-GAAP Financial Measures" above for more information on how we
calculate Adjusted EPS.
|
|
In millions, except per share amounts
|
|
Year Ending
December 31, 2017
|
|
|
|
|
|
Income before income
tax provision(1)
|
|
$
|
8,835
|
|
|
$
|
9,152
|
|
Non-GAAP
adjustments:
|
|
|
|
|
Amortization of
intangible assets
|
|
820
|
|
|
820
|
|
Pension
settlement
|
|
220
|
|
|
220
|
|
Adjusted income
before income tax provision
|
|
9,875
|
|
|
10,192
|
|
Adjusted income tax
provision
|
|
3,841
|
|
|
3,985
|
|
Adjusted income from
continuing operations
|
|
6,034
|
|
|
6,207
|
|
Net income
attributable to noncontrolling interest
|
|
(2)
|
|
|
(2)
|
|
Income allocable to
participating securities
|
|
(33)
|
|
|
(33)
|
|
Adjusted income from
continuing operations attributable to CVS Health
|
|
$
|
5,999
|
|
|
$
|
6,172
|
|
|
|
|
|
|
Weighted average
diluted shares outstanding
|
|
1,040
|
|
|
1,040
|
|
Adjusted earnings per
share
|
|
$
|
5.77
|
|
|
$
|
5.93
|
|
|
(1) Estimated
integration costs related to the acquisition of Omnicare are
excluded from the 2017 Preliminary Outlook.
|
Logo -
http://photos.prnewswire.com/prnh/20140905/143455
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cvs-health-reports-third-quarter-results-300359001.html
SOURCE CVS Health Corporation